


IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

VALUE DRUG COMPANY	:	CIVIL ACTION
	:	
v.	:	NO. 21-3500
	:	
TAKEDA PHARMACEUTICALS,	:	
U.S.A., INC., PAR	:	
PHARMACEUTICAL, INC., WATSON	:	
LABORATORIES, INC., TEVA	:	
PHARMACEUTICAL INDUSTRIES,	:	
LTD., TEVA PHARMACEUTICALS	:	
USA, INC., AMNEAL	:	
PHARMACEUTICALS, LLC	:	

ORDER

AND NOW, this 23rd day of November 2022, upon considering Plaintiff's Motion to certify a class (ECF Doc. No. 483), Defendants' Response (ECF Doc. No. 527), Plaintiff's Reply (ECF Doc. No. 543), the parties' pre-hearing Memoranda (ECF Doc. Nos. 592, 593), following our extensive November 1, 2022 evidentiary hearing and oral argument, and for reasons in the accompanying Memorandum, it is **ORDERED** Plaintiff's Motion to certify a class (ECF Doc. No. 483) is **DENIED** without prejudice.


KEARNEY, J.